Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.16
NVGN's Cash to Debt is ranked higher than
68% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. NVGN: 2.16 )
NVGN' s 10-Year Cash to Debt Range
Min: 2.16   Max: No Debt
Current: 2.16

Equity to Asset 0.70
NVGN's Equity to Asset is ranked higher than
76% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. NVGN: 0.70 )
NVGN' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.86
Current: 0.7

0.33
0.86
F-Score: 2
Z-Score: -24.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -79.54
NVGN's Operating margin (%) is ranked lower than
52% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.93 vs. NVGN: -79.54 )
NVGN' s 10-Year Operating margin (%) Range
Min: -882.08   Max: -31.89
Current: -79.54

-882.08
-31.89
Net-margin (%) -59.60
NVGN's Net-margin (%) is ranked lower than
51% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. NVGN: -59.60 )
NVGN' s 10-Year Net-margin (%) Range
Min: -689.28   Max: 55.14
Current: -59.6

-689.28
55.14
ROE (%) -25.51
NVGN's ROE (%) is ranked lower than
51% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NVGN: -25.51 )
NVGN' s 10-Year ROE (%) Range
Min: -153.65   Max: 37.66
Current: -25.51

-153.65
37.66
ROA (%) -17.93
NVGN's ROA (%) is ranked higher than
50% of the 748 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. NVGN: -17.93 )
NVGN' s 10-Year ROA (%) Range
Min: -64   Max: 14.57
Current: -17.93

-64
14.57
ROC (Joel Greenblatt) (%) -11466.67
NVGN's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. NVGN: -11466.67 )
NVGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16308.96   Max: -57.68
Current: -11466.67

-16308.96
-57.68
Revenue Growth (%) 809.40
NVGN's Revenue Growth (%) is ranked higher than
100% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NVGN: 809.40 )
NVGN' s 10-Year Revenue Growth (%) Range
Min: -51   Max: 809.4
Current: 809.4

-51
809.4
EBITDA Growth (%) 292.10
NVGN's EBITDA Growth (%) is ranked higher than
100% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. NVGN: 292.10 )
NVGN' s 10-Year EBITDA Growth (%) Range
Min: -23.9   Max: 292.1
Current: 292.1

-23.9
292.1
EPS Growth (%) 116.50
NVGN's EPS Growth (%) is ranked higher than
98% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. NVGN: 116.50 )
NVGN' s 10-Year EPS Growth (%) Range
Min: -27.5   Max: 116.5
Current: 116.5

-27.5
116.5
» NVGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

NVGN Guru Trades in Q4 2012

Jim Simons 48,940 sh (+4.93%)
Ronald Muhlenkamp 18,184 sh (-49.15%)
» More
Q1 2013

NVGN Guru Trades in Q1 2013

Ronald Muhlenkamp Sold Out
Jim Simons 44,940 sh (-8.17%)
» More
Q2 2013

NVGN Guru Trades in Q2 2013

Jim Simons 15,240 sh (-66.09%)
» More
Q3 2013

NVGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2013-03-31 Sold Out 0.03%$1.84 - $9.05 $ 3.24-15%0
Ronald Muhlenkamp 2012-12-31 Reduce -49.15%0.01%$1.5 - $10.24 $ 3.24-35%18184
Ronald Muhlenkamp 2012-06-30 New Buy0.02%$1.95 - $2.5 $ 3.2443%35757
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.80
NVGN's P/B is ranked higher than
59% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. NVGN: 4.80 )
NVGN' s 10-Year P/B Range
Min: 0.95   Max: 13.11
Current: 4.8

0.95
13.11
P/S 2.60
NVGN's P/S is ranked higher than
100% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. NVGN: 2.60 )
NVGN' s 10-Year P/S Range
Min: 0   Max: 37.69
Current: 2.6

0
37.69
EV-to-EBIT -15.82
NVGN's EV-to-EBIT is ranked lower than
59% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.81 vs. NVGN: -15.82 )
NVGN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -15.82

Current Ratio 1.84
NVGN's Current Ratio is ranked higher than
63% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. NVGN: 1.84 )
NVGN' s 10-Year Current Ratio Range
Min: 1.54   Max: 9.78
Current: 1.84

1.54
9.78
Quick Ratio 1.84
NVGN's Quick Ratio is ranked higher than
72% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. NVGN: 1.84 )
NVGN' s 10-Year Quick Ratio Range
Min: 1.46   Max: 8.68
Current: 1.84

1.46
8.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.70
NVGN's Price/Net Cash is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NVGN: 14.70 )
NVGN' s 10-Year Price/Net Cash Range
Min: 2.36   Max: 23.3
Current: 14.7

2.36
23.3
Price/Net Current Asset Value 14.10
NVGN's Price/Net Current Asset Value is ranked higher than
83% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NVGN: 14.10 )
NVGN' s 10-Year Price/Net Current Asset Value Range
Min: 1.83   Max: 19.5
Current: 14.1

1.83
19.5
Price/Tangible Book 13.00
NVGN's Price/Tangible Book is ranked higher than
53% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NVGN: 13.00 )
NVGN' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 19.5
Current: 13

1.5
19.5
Forward Rate of Return (Yacktman) -16339.86
NVGN's Forward Rate of Return (Yacktman) is ranked lower than
56% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. NVGN: -16339.86 )
NVGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -16339.86

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NRT.Australia, NV9.Germany, NV9B.Germany
Novogen Ltd. research, develops & markets pharmaceutical products. It offers its products therapeutic area cancer, heart disease, inflammatory bowel disease & other chronic inflammatory diseases & also provides health supplements.
» More Articles for NAS:NVGN

Headlines

Articles On GuruFocus.com
comment on NVGN Mar 06 2013 

More From Other Websites
Novogen And CanTx Appoint Contract Manufacturers To Produce Clinical Batches Of Cantrixil™ Jul 25 2014
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant... Jun 17 2014
5 Reasons Why We Believe Novogen Is Poised For Success Jun 05 2014
Novogen rises 14.7% May 27 2014
Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer May 27 2014
Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for... May 04 2014
Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative... May 02 2014
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo Mar 18 2014
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York Mar 12 2014
Novogen Selected to Present at Cavendish Global Health Impact Forum Mar 10 2014
Novogen appoints David Gryska as strategic advisor Mar 04 2014
Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical... Mar 04 2014
Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform Feb 03 2014
Novogen to Host Corporate Update and Webcast Jan 30 2014
Novogen to Present at Biotech Showcase™ 2014 Jan 08 2014
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat... Dec 20 2013
Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology Nov 26 2013
Wal-Mart’s Soft Quarter, Rio Tinto’s Arizona Mine Project, and 3 More Hot Stocks Nov 14 2013
NOVOGEN LTD Financials Nov 07 2013
Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer Nov 06 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide